Replay available

Schrodinger, Inc. (SDGR) Q2 2026 Earnings Call

Schrodinger, Inc. (NASDAQ: SDGR) Q2 2026 earnings conference call, held 2026-08-05. Replay captured from the company's public earnings webcast.

Wed, August 5, 2026 at 4:30 PMendedReplay
Schrodinger, Inc. (SDGR) Q2 2026 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Jaren Madden

Chief Corporate Affairs Officer and Head of Investor Relations

Ramy Farid

Chief Executive Officer

Richie Jain

Chief Financial Officer

Karen Akinsanya

President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships

Alexa Chan

Analyst, Bank of America

Matt Hewitt

Analyst, Craig-Hallam Capital Group

Scott Schoenhaus

Analyst, KeyBank

Pat Lorton

Chief Technology and Chief Operating Officer

Unknown Speaker

Brendan Smith

Analyst, TD Cowen

Replay transcript excerpt

Thank you for standing by. Welcome to Schrodinger's conference call to review second quarter 2026 financial results. My name is Rob and I will be your operator for today's call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, simply press star, then the number one on your telephone keypad. Please be advised that this call is being recorded at the company's request. Now I would like to introduce your host for today's conference, Ms. Jaren Madden, Chief Corporate Affairs Officer and Head of Investor Relations. Please go ahead. Thank you and good afternoon, everyone. Welcome to today's call, during which we will provide an update on the company and review our second quarter 2026 financial results. Earlier today, we issued the press release summarizing our financial results and progress across the company, which is available on our website at schrodinger.com. During today's call, management will make statements that are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to our outlook for the full year 2026 and Third Quarter 2026, our plans to accelerate the growth of our software business and advance our therapeutics portfolio, the capabilities and potential advantages of Bunsen, our agentic AI co-scientist, the clinical potential and properties of our and our collaborators' compounds, the use of our cash resources, as well as our future expenses. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information cu...

More from Schrodinger, Inc.